# A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older

> **NCT01646398** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 764 (actual)

## Conditions studied

- Pneumococcal Vaccines
- Pneumococcal Conjugate Vaccine

## Interventions

- **BIOLOGICAL:** 13-valent pneumococcal conjugate vaccine
- **BIOLOGICAL:** 23-valent pneumococcal polysaccharide vaccine

## Key facts

- **NCT ID:** NCT01646398
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 764 (ACTUAL)
- **Last updated:** 2013-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01646398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01646398, "A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01646398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*